In that same briefing note, you said that after five years, myriad policy proposals and many hundreds of hours of consultation, it would appear that the pharmaceutical industry is simply not amenable to any measure that would further constrain its ability to sell patented medicines in Canada at free-market prices.
Do you stand by that opinion?